- Home
- PMCB vs AIM Comparison
PMCB vs AIM Comparison
Compare PMCB & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- AIM
- Stock Information
- Founded
- PMCB 1996
- AIM 1966
- Country
- PMCB United States
- AIM United States
- Employees
- PMCB N/A
- AIM N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMCB Health Care
- AIM Health Care
- Exchange
- PMCB Nasdaq
- AIM Nasdaq
- Market Cap
- PMCB 11.4M
- AIM 9.8M
- IPO Year
- PMCB N/A
- AIM N/A
- Fundamental
- Price
- PMCB $1.78
- AIM $0.13
- Analyst Decision
- PMCB
- AIM Strong Buy
- Analyst Count
- PMCB 0
- AIM 2
- Target Price
- PMCB N/A
- AIM $2.75
- AVG Volume (30 Days)
- PMCB 27.8K
- AIM 1.6M
- Earning Date
- PMCB 03-17-2025
- AIM 04-01-2025
- Dividend Yield
- PMCB N/A
- AIM N/A
- EPS Growth
- PMCB N/A
- AIM N/A
- EPS
- PMCB 0.74
- AIM N/A
- Revenue
- PMCB N/A
- AIM $190,000.00
- Revenue This Year
- PMCB N/A
- AIM N/A
- Revenue Next Year
- PMCB N/A
- AIM $1,693.10
- P/E Ratio
- PMCB $2.40
- AIM N/A
- Revenue Growth
- PMCB N/A
- AIM N/A
- 52 Week Low
- PMCB $1.39
- AIM $0.11
- 52 Week High
- PMCB $2.58
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- PMCB 56.75
- AIM 43.31
- Support Level
- PMCB $1.57
- AIM $0.11
- Resistance Level
- PMCB $1.80
- AIM $0.16
- Average True Range (ATR)
- PMCB 0.13
- AIM 0.02
- MACD
- PMCB 0.01
- AIM 0.00
- Stochastic Oscillator
- PMCB 64.10
- AIM 46.00
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.